GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONCW) » Definitions » EV-to-EBIT

American Oncology Network (American Oncology Network) EV-to-EBIT : 0.00 (As of Jun. 19, 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, American Oncology Network's Enterprise Value is $0.00 Mil. American Oncology Network's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-68.04 Mil. Therefore, American Oncology Network's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for American Oncology Network's EV-to-EBIT or its related term are showing as below:

During the past 4 years, the highest EV-to-EBIT of American Oncology Network was 18.19. The lowest was -30.24. And the median was -7.48.

AONCW's EV-to-EBIT is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 17.15
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. American Oncology Network's Enterprise Value for the quarter that ended in Mar. 2024 was $0.00 Mil. American Oncology Network's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-68.04 Mil. American Oncology Network's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.

American Oncology Network EV-to-EBIT Historical Data

The historical data trend for American Oncology Network's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network EV-to-EBIT Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - - -6.29

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial - - -23.43 -6.29 -4.47

Competitive Comparison of American Oncology Network's EV-to-EBIT

For the Medical Care Facilities subindustry, American Oncology Network's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

American Oncology Network's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, American Oncology Network's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where American Oncology Network's EV-to-EBIT falls into.


American Oncology Network EV-to-EBIT Calculation

American Oncology Network's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-68.039
=0.00

American Oncology Network's current Enterprise Value is $0.00 Mil.
American Oncology Network's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-68.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

American Oncology Network  (OTCPK:AONCW) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

American Oncology Network's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-68.039/0
= %

American Oncology Network's Enterprise Value for the quarter that ended in Mar. 2024 was $0.00 Mil.
American Oncology Network's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-68.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

American Oncology Network EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of American Oncology Network's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

American Oncology Network (American Oncology Network) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONCW) » Definitions » EV-to-EBIT
Comparable Companies
PIII TOI BTMD AVAH CYH JYNT PNTG SNDA AIRS CCM HCA SAU:4013 SZSE:300015 HKSE:06618 XTER:FRE BKK:BDMS XKLS:5225 BSP:RDOR3 XTER:FME UHS
Traded in Other Exchanges
AONC:USA
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
Website
https://www.aoncology.com
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.